KNSA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
286.0M
+17.4%
243.6M
+13.7%
214.3M
+6.0%
202.1M
+11.8%
180.9M
Cost of Revenue
27.8M
+17.8%
23.6M
+13.3%
20.8M
-0.7%
20.9M
+3.4%
20.3M
Gross Profit
258.2M
+17.4%
220.0M
+13.7%
193.5M
+6.8%
181.2M
+12.8%
160.6M
Operating Expenses
204.0M
+5.8%
192.8M
+17.4%
164.2M
+1.7%
161.4M
+18.2%
136.6M
R&D
32.8M
-19.8%
40.9M
+48.9%
27.5M
-20.6%
34.6M
+43.2%
24.2M
SG&A
65.4M
+2.3%
63.9M
+4.4%
61.2M
+7.7%
56.8M
+15.6%
49.1M
Operating Income
54.2M
+99.4%
27.2M
-7.1%
29.3M
+48.1%
19.8M
-17.7%
24.0M
EBITDA
54.7M
+97.8%
27.7M
-7.0%
29.7M
+46.9%
20.2M
-17.1%
24.4M
Net Income
47.3M
+86.2%
25.4M
+12.6%
22.6M
+59.1%
14.2M
-23.0%
18.4M
EPS (Basic)
$0.61
+84.8%
$0.33
+10.0%
$0.30
+57.9%
$0.19
-24.0%
$0.25
EPS (Diluted)
$0.56
+86.7%
$0.30
+11.1%
$0.27
+58.8%
$0.17
-26.1%
$0.23
Shares (Diluted)
84.9M
+1.8%
83.4M
+1.2%
82.4M
+0.8%
81.8M
+2.2%
80.0M
Kiniksa Pharmaceuticals International (KNSA) — Financials